Back to Search
KERRI AN MROSS, MD
MD
Internal Medicine Physician
NPI: 1295780195IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
D0063347(MD)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
VIRGINIA COMMONWEALTH UNIVERSITY, SCHOOL OF MEDICINE
Class of 2002
Research & Publications (20)
First-in-man and first-of-class-in-man clinical trials in oncology.
PMID 19203543·Int J Clin Pharmacol Ther·2009
8-other
Risk assessment of Bundeswehr (German Federal Armed Forces) permethrin-impregnated battle dress uniforms (BDU).
PMID 18222725·Int J Hyg Environ Health·2008
6-review
[Inhibition of the VEGF receptor system with tyrosine kinase inhibitors. Angiogenesis inhibition in oncology].
PMID 18729270·Pharm Unserer Zeit·2008
6-review
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
PMID 18955456·J Clin Oncol·2008
3-trial
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours.
PMID 19002179·Br J Cancer·2008
3-trial
Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.
PMID 18063875·Onkologie·2007
3-trial
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
PMID 17095207·Eur J Cancer·2007
3-trial
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
PMID 17186002·Clin Pharmacol Ther·2007
7-preclinical
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
PMID 17634482·J Clin Oncol·2007
3-trial
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
PMID 18040273·Br J Cancer·2007
3-trial
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
PMID 17699865·Clin Cancer Res·2007
3-trial
Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
PMID 16874015·Onkologie·2006
5-case
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
PMID 16950614·Eur J Cancer·2006
8-other
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
PMID 16293411·Eur J Cancer·2006
6-review
PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
PMID 17028453·Onkologie·2006
3-trial
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
PMID 15955899·J Clin Oncol·2005
3-trial
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
PMID 16000582·Clin Cancer Res·2005
3-trial
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
PMID 16299241·Clin Cancer Res·2005
3-trial
Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications.
PMID 16372534·Int J Clin Pharmacol Ther·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3100 WYMAN PARK DR, DEPT OF MEDICINE
BALTIMORE, MD 21211 - Phone
- (410) 338-3500
Quick Facts
- NPI
- 1295780195
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 24
- Publications
- 20
Are you this provider?
Claim Your Profile